Acrivon Therapeutics, Inc.
ACRVNasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$84.1M | −$89.2M | −$67.1M | −$32.7M | −$16.2M |
| Net income | −$77.9M | −$80.6M | −$60.4M | −$31.2M | −$16.2M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M |
| Equity | $112.5M | $176.8M | $121.2M | $170.5M | −$23.8M |
| EPS (diluted) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 |
| Shares out. | 31.4M | 22.6M | 21.9M | 21.9M | 1.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.2%
- Return on assets
- −60.1%
- Return on capital (ROCE)
- −73.7%
- Liabilities / assets
- 13.3%
- Debt / equity
- 0.15×
- Book value / share
- $3.59
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.90distress
- Accruals / assets
- −11.0%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-08-12Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
- Phase 2Recruitingreadout ~2027-05-30A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Citadel Advisors LlcPassive (13G)May 15, 2026
- Ra Capital Management, L.P.Activist (13D)Apr 23, 2026
- Sands Capital Life Sciences Pulse Fund Ii, L.P.Passive (13G)Aug 13, 2025
- Perceptive Advisors LlcPassive (13G)Jun 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Blume-Jensen PeterOfficer — President and CEO | May 21, 2026 | Tax withholding | 13,729 | $1.79 |
| Ra Capital Management, L.P.Director | May 18, 2026 | Grant | 9,366 | $0.00 |
| Tomsicek Michael JohnDirector | May 18, 2026 | Grant | 9,366 | $0.00 |
| Shacham SharonDirector | May 18, 2026 | Grant | 9,366 | $0.00 |
| Palani SanthoshDirector | May 18, 2026 | Grant | 9,366 | $0.00 |
| Magovcevic-Liebisch IvanaDirector | May 18, 2026 | Grant | 9,366 | $0.00 |
| Dirocco DerekDirector | May 18, 2026 | Grant | 9,366 | $0.00 |
| Baum Charles MDirector | May 18, 2026 | Grant | 9,366 | $0.00 |
| Peterson KatharineOfficer — Chief Accounting Officer | May 18, 2026 | Grant | 14,227 | $0.00 |
| Mirza Mansoor RazaOfficer — Chief Medical Officer | May 18, 2026 | Grant | 38,817 | $0.00 |
| Miller MaryOfficer — Chief Legal Officer | May 18, 2026 | Grant | 49,830 | $0.00 |
| Levy Adam D.Officer — Chief Financial Officer | May 18, 2026 | Grant | 46,167 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 4.4 | +1.3% |
| Apr 30, 2026 | 2.5M | 2.3 | +3.2% |
| Apr 15, 2026 | 2.4M | 4.2 | +9.3% |
| Mar 31, 2026 | 2.2M | 3.4 | -9.2% |
| Mar 13, 2026 | 2.4M | 2.8 | +12.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Results of operations · Regulation FD disclosureMar 19, 2026
- Terminated a material agreementMar 2, 2026
- Regulation FD disclosureFeb 27, 2026
- Regulation FD disclosureJan 8, 2026
- Results of operations · Regulation FD disclosure · Other material eventJan 8, 2026
- Results of operationsNov 13, 2025
- Regulation FD disclosureSep 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.